Mark Scott

With more than a decade in drug discovery and development, Mark is focused on supporting pipeline development activities through the development of processes and their controls to enable the consistent delivery of high quality drug substance and drug product materials for patients.

In his time in industry, Mark has contributed to the discovery and development of numerous pre-clinical, clinical, and commercial compounds including niraparib, voxilaprevir, and more recently firsocostat for the treatment of NASH (non-alcoholic steatohepatitis).

Outside of work, Mark is an avid gardener who enjoys trips to the mountains and numerous outdoor activities with his wife and two children.